Overview

Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Everolimus is effective in the treatment and prevention of chronic graft dysfunction and chronic graft rejection after lung transplantation.
Phase:
Phase 3
Details
Lead Sponsor:
Hannover Medical School
Collaborator:
Novartis Pharmaceuticals
Treatments:
Everolimus
Immunosuppressive Agents
Sirolimus